Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature ...
Early data indicates that TransCon CNP could challenge Voxzogo's market share by late 2025. Ascendis' TransCon CNP stands out due to its once-weekly dosing schedule and potentially improved safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results